Vivos Therapeutics, Inc. (VVOS) Misses Q2 EPS by 1c

Vivos Therapeutics, Inc. (NASDAQ: VVOS) reported Q2 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $3.4 million versus the consensus estimate of $4.42 million.

For earnings history and earnings-related data on Vivos Therapeutics, Inc. (VVOS) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• KeyBanc on National Fuel Gas (NFG): 'P&S Growth an Underappreciated Hedge to Weak Natural Gas Prices'
• Citi sees tower stocks benefiting from potential Starlink network build